Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $22.5 million.

  • Lifecore Biomedical, Inc. \De\'s Cost of Revenue rose 896.48% to $22.5 million in Q2 2025 from the same period last year, while for May 2025 it was $88.6 million, marking a year-over-year increase of 249.74%. This contributed to the annual value of $88.6 million for FY2025, which is 249.74% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Cost of Revenue amounted to $22.5 million in Q2 2025, which was up 896.48% from $25.3 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Cost of Revenue ranged from a high of $25.3 million in Q1 2025 and a low of -$27.7 million during Q2 2022
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Cost of Revenue had a median value of $19.8 million in 2023 and averaged $17.1 million.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Cost of Revenue crashed by 28890.94% in 2022 and then surged by 18436.96% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Cost of Revenue (Quarter) stood at $14.1 million in 2021, then increased by 14.44% to $16.2 million in 2022, then rose by 24.76% to $20.2 million in 2023, then rose by 6.37% to $21.5 million in 2024, then increased by 4.57% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q2 2025, $25.3 million for Q1 2025, and $21.5 million during Q4 2024.